Recent advances in the treatment of multiple myeloma have increased the need for accurate
diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the …

Acknowledging the increasingly important role of whole-body MRI for directing patient care
in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical …

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …

PURPOSE 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed
tomography (CT) is currently the standard technique to define minimal residual disease …

Patients with multiple myeloma (MM) carrying standard-or high-risk cytogenetic
abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior …

Minimal residual disease (MRD) assessment is incorporated in an increasing number of
multiple myeloma (MM) clinical trials as a correlative analysis, an endpoint or even as a …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis,
workup, treatment, follow-up, and supportive care for patients with monoclonal gammopathy …

The iliac crest is the sampling site for minimal residual disease (MRD) monitoring in multiple
myeloma (MM). However, the disease distribution is often heterogeneous, and imaging can …

Bone disease is the most frequent feature of multiple myeloma (MM) and represents a
marker of end-organ damage; it is used to establish the diagnosis and to dictate the …

Multiple myeloma (MM) is a clonal plasma cell proliferative disorder characterized by
primary infiltration of bone marrow and excessive production of abnormal immunoglobulin …